Lisa Campo-Engelstein

From WikiMD's Food, Medicine & Wellness Encyclopedia

BBC 100 Women Lisa Campo-Engelstein PhD (cropped)

Lisa Campo-Engelstein is an American bioethicist and a prominent figure in the field of reproductive ethics. She is known for her work on gender and reproductive technology, particularly focusing on the ethical implications of contraception and fertility preservation.

Early Life and Education[edit | edit source]

Lisa Campo-Engelstein earned her B.A. in Philosophy from Middlebury College. She then pursued her M.A. and Ph.D. in Philosophy with a concentration in Bioethics from Michigan State University.

Career[edit | edit source]

Campo-Engelstein is currently an Associate Professor at the University of Texas Medical Branch (UTMB) in the Department of Preventive Medicine and Community Health. She also holds a joint appointment in the Department of Obstetrics and Gynecology.

Her research primarily focuses on the ethical, social, and cultural implications of reproductive technologies. She has published extensively on topics such as male contraception, fertility preservation for cancer patients, and the gendered aspects of reproductive health.

Research Interests[edit | edit source]

Campo-Engelstein's research interests include:

Selected Publications[edit | edit source]

Some of her notable publications include:

  • "The Ethics of Male Contraception"
  • "Fertility Preservation for Cancer Patients: Ethical Considerations"
  • "Gender and Reproductive Technology: Ethical Perspectives"

Awards and Honors[edit | edit source]

Campo-Engelstein has received several awards for her contributions to the field of bioethics, including the American Society for Bioethics and Humanities (ASBH) Early Career Award.

Related Pages[edit | edit source]

Categories[edit | edit source]




Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD